Pirfenidone improves survival in IPF: results from a real-life study
Authors:
Open Access
- 23 November 2018
- journal article
- research article
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 18 (1) , 1-7
Abstract
Pirfenidone is an antifibrotic compound approved for the treatment of idiopathic pulmonary fibrosis (IPF). We present our real-world experience in terms of Pirfenidone’s effect on mortality and adverse events profile outside the restrictions of a clinical trial. This is a retrospective observational intention to treat study of 82 consecutive IPF patients (UHH cohort). We observed a high 3-years survival rate of 73% without excluding patients who discontinued treatment for different reasons. The survival was compared to the survival of an IPF cohort from a tertiary referral center (RBH cohort). After exclusion of severe cases (DLco< 30%), in unadjusted analysis, the survival in the UHH cohort was better than in the RBH cohort (HR:0.32, 95% CI: 0.19–0.53, p < 0.0001). After adjustment for age, gender and FVC, the survival remained higher in the UHH cohort (HR:0.28, 95% CI: 0.16–0.48, p < 0.0001). We observed a similar safety profile compared to previously published data and a lower rate of drug discontinuation due to photosensitivity reactions. Conclusion: Pirfenidone provides a survival benefit in a real-life IPF cohort compared to previously used medications. Counselling patients and proactively managing possible adverse effects can reduce the necessity to discontinue pirfenidone.Keywords
This publication has 25 references indexed in Scilit:
- A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary FibrosisNew England Journal of Medicine, 2014
- Hot of the breath: Mortality as a primary end-point in IPF treatment trials: the best is the enemy of the goodThorax, 2012
- Prednisone, Azathioprine, andN-Acetylcysteine for Pulmonary FibrosisNew England Journal of Medicine, 2012
- Recent advances in the pathogenesis and clinical evaluation of pulmonary fibrosisEuropean Respiratory Review, 2012
- Predicting survival in newly diagnosed idiopathic pulmonary fibrosis: a 3-year prospective studyEuropean Respiratory Journal, 2012
- Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trialsThe Lancet, 2011
- An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and ManagementAmerican Journal of Respiratory and Critical Care Medicine, 2011
- Bias due to withdrawal in long‐term randomised trials in COPD: Evidence from the TORCH studyThe Clinical Respiratory Journal, 2010
- Clinical outcomes according to permanent discontinuation of clopidogrel or placebo in the CHARISMA trialArchives of Cardiovascular Diseases, 2009
- Idiopathic Pulmonary Fibrosis: A Composite Physiologic Index Derived from Disease Extent Observed by Computed TomographyAmerican Journal of Respiratory and Critical Care Medicine, 2003